Peptide reference

GHK-Cu

Glycyl-L-histidyl-L-lysine copper(II) · a naturally occurring copper-binding tripeptide

A three-amino-acid peptide found in human plasma that binds copper(II) with high affinity — and whose concentration falls markedly with age.

Residues

3

Complex formula

C14H22CuN6O4

Molecular weight

~403.9 g/mol

INCI name

Copper Tripeptide-1

Cu²⁺GHK

Researched effects

GHK-Cu has more direct human data than most peptides in this category, but that data is overwhelmingly small topical cosmetic studies, not large clinical trials.

Collagen synthesis

Stimulates collagen production in dermal fibroblasts.

In vitroHuman topical trials

Elastin and glycosaminoglycans

Increased synthesis of dermal matrix components.

In vitro

Decorin upregulation

A proteoglycan involved in ordered collagen fibril assembly.

In vitro

Wound healing

Improved healing rates in animal wound models.

Rodent studies

Skin appearance

Improvements in firmness, elasticity and fine lines in small cosmetic trials.

Human topical trials

Antioxidant activity

Copper delivery to superoxide dismutase; reduction of lipid peroxidation.

In vitro

Anti-inflammatory signalling

Modulation of inflammatory mediators.

In vitro

Hair follicle stimulation

Increased follicle size and growth in models.

Rodent studiesIn vitro

Broad gene expression modulation

Connectivity Map analysis reported GHK shifting the expression of a large number of human genes toward a healthier profile.

Gene expression analysis

Sequence & coordination

Three residues, N-terminus to C-terminus, with copper(II) bound at the centre. Toggle the view to see what changes on binding.

Cu²⁺GHK

Hover or focus a residue to inspect. Dashed lines are Cu(II) coordination bonds: to the N-terminal amine, to the imidazole nitrogen of His-2, and to the deprotonated backbone amide nitrogen between Gly-1 and His-2.

Amino acid composition

At three residues, composition is trivially even — each residue is exactly one third of the chain.

3residues

At length 3 each residue is exactly 33.3% — composition percentages are trivial here; the story is the roles.

Glypos 1 · 33.3%

Glycine · Structural

Free N-terminal amine donates to Cu(II).

Hispos 2 · 33.3%

Histidine · Aromatic

Imidazole nitrogen is the key Cu(II) anchor.

Lyspos 3 · 33.3%

Lysine · Basic

Side-chain amine drives net positive charge and membrane affinity.

Structural properties

Four readouts characterising the tripeptide and its complex.

Readout · 01

High-affinity copper(II) binding

The defining property. GHK binds Cu(II) tightly enough to exchange copper with albumin in plasma.

Readout · 02

Net charge ≈ +2 (free peptide)

No acidic residues. The N-terminal amine and lysine side chain both carry positive charge at physiological pH.

Readout · 03

No cysteine, no proline

No disulphide bonds and no proline-driven backbone rigidity — a simple, small, flexible chain.

Readout · 04

Very small

3 residues, ~340 Da free / ~404 Da complexed — far smaller than typical bioactive peptides, central to topical formulation use.

Plasma decline with age

Widely cited figures from the foundational literature — population estimates, not a diagnostic reference range.

Plasma GHK falls from ~200 ng/mL around age 20 to ~80 ng/mL by age 60.

Proposed mechanisms

Pathways inferred from in vitro and animal work. Proposed rather than confirmed in humans.

Proposed · in vitro / animal basis
GHK-Cu
Copper delivery to cells
Lysyl oxidase activation
Collagen & elastin cross-linking
Copper → superoxide dismutase → antioxidant capacity
TGF-β signalling → fibroblast activation → matrix synthesis
Broad transcriptional modulation → tissue-remodelling gene programmes

Regulatory status

Established cosmetic ingredient.

Copper Tripeptide-1 is a recognised cosmetic ingredient used in topical skincare in the US, UK and EU.

Not an approved medicine.

No marketing authorisation as a drug; injectable use is not an approved route and is not a licensed medicinal use.

Evidence quality.

Topical human evidence exists but comes largely from small, industry-adjacent cosmetic studies. Systemic and injectable use is not supported by comparable data.